<DOC>
	<DOCNO>NCT00998686</DOCNO>
	<brief_summary>The purpose study demonstrate safety tolerability dutogliptin 52 week .</brief_summary>
	<brief_title>Safety Efficacy Study Dutogliptin Subjects With Type 2 Diabetes Mellitus Background Medication Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Completion require visit qualify Phase 3 core protocol Current treatment Type 2 diabetes mellitus PHX1149PROT302 Any condition , disease , disorder clinically relevant laboratory abnormality , opinion investigator , would jeopardize patient 's appropriate participation study obscure effect treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>diabetes</keyword>
	<keyword>DPP4 inhibitor</keyword>
	<keyword>dutogliptin</keyword>
</DOC>